RGene Therapeutics Inc., Targeted Genetics deal

The companies signed a definitive agreement under which TGEN will acquire RGene for 3.6 million unregistered shares of common stock. TGEN, which closed at $5.50 on Friday, has 12.4 million shares outstanding prior to the acquisition.

Privately held RGene is developing a non-viral gene delivery technology using cationic lipids that promote the uptake of DNA into cells. RGene is conducting a Phase I trial of its EIA tumor suppressor gene in ovarian and breast cancer. ...